Profile data is unavailable for this security.
About the company
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-11.60m
- Incorporated2014
- Employees10.00
- LocationBio Path Holdings Inc4710 BELLAIRE BOULEVARD, SUITE 210BELLAIRE 77401United StatesUSA
- Phone+1 (832) 742-1357
- Fax+1 (916) 443-1908
- Websitehttps://www.biopathholdings.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
InMed Pharmaceuticals Inc | 4.60m | -7.68m | 2.78m | 13.00 | -- | 0.202 | -- | 0.605 | -1.33 | -1.33 | 0.6027 | 1.03 | 0.3546 | 2.44 | 14.99 | -- | -59.20 | -92.09 | -69.92 | -113.17 | 23.94 | -- | -166.94 | -543.29 | 3.78 | -- | 0.00 | -- | 11.18 | -- | 3.42 | -- | -19.10 | -- |
Halberd Corp | 281.24k | 25.34k | 2.80m | 3.00 | 1.90 | -- | 110.28 | 9.95 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
Avenue Therapeutics Inc | 0.00 | -5.87m | 2.82m | 3.00 | -- | 0.492 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
Bio Path Holdings Inc | 0.00 | -11.60m | 3.04m | 10.00 | -- | 2.10 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
Revelation Biosciences Inc | 0.00 | -15.90m | 3.04m | 9.00 | -- | 1.17 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
Oragenics Inc | 7.47k | -19.52m | 3.12m | 5.00 | -- | -- | -- | 417.30 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
Talis Biomedical Corp | 408.00k | -51.03m | 3.13m | 99.00 | -- | 0.0645 | -- | 7.68 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
Therapeutic Solutions International Inc | 91.38k | -2.00m | 3.17m | 3.00 | -- | 2.30 | -- | 34.74 | -0.0005 | -0.0005 | 0.00002 | 0.0003 | 0.0252 | 1.29 | 5.24 | 30,460.00 | -63.67 | -162.32 | -153.29 | -- | 65.18 | 67.79 | -2,530.31 | -2,391.85 | 0.3883 | -6.94 | 0.3164 | -- | -52.13 | 95.35 | 43.11 | -- | -- | -- |
Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.19m | 21.00 | -- | 0.3825 | -- | 0.774 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
Biostax Corp | 0.00 | -1.51m | 3.27m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.27m | 5.00 | -- | 1.82 | -- | 6.45 | -0.6188 | -0.6188 | 0.074 | 0.224 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.34m | 24.00 | -- | -- | -- | 0.2778 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 13.50k | 0.65% |
Geode Capital Management LLCas of 30 Jun 2024 | 10.87k | 0.52% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.38k | 0.11% |
Tower Research Capital LLCas of 31 Mar 2024 | 1.93k | 0.09% |
UBS Securities LLCas of 31 Mar 2024 | 1.18k | 0.06% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 35.00 | 0.00% |
Group One Trading LPas of 31 Mar 2024 | 21.00 | 0.00% |
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 7.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 4.00 | 0.00% |
Global Retirement Partners LLCas of 30 Jun 2024 | 4.00 | 0.00% |